Table 4.
Pros | Latest developments | Who is working on this strategy | |
---|---|---|---|
Carmoterol+budesonide | It is twofold more effective than the formoterol/budesonide combination | Preclinical phase | Chiesi |
Indacaterol+mometasone (QMF149) | It has a superior delivery profile than formoterol/budesonide owing to its once-daily dosing | Phase III | Novartis |
ICS, inhaled corticosteroid.
LABA, long-acting β-agonist.